The identified targets included 40 druggable PD-L1 enhancers whose perturbation by associated drugs might downregulate PD-L1 expression and nine cancer drivers and seven cancer drivers that enhance or suppress PD-L1 expression, respectively (Supplementary Table 3). This evidence concerns the gene CD274 and cancer.